Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR/HER2 Dual-Target CAR-NK Cells in Recurrent or Metastatic HNSCC
NCT07617805Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in head and neck squamous cell carcinoma (HNSCC), sponsored by Biotech Pharmaceutical. Primary endpoints: Incidence of dose-limiting toxicities at 28 days and Recommended Phase 2 Dose. Started Mar 2026; status: recruiting.
02
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07617805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07617805.